熱門資訊> 正文
Royalty Pharma与强生合作提供5亿美元的研发资金
2026-03-30 19:45
- Royalty Pharma (RPRX) is partnering with Johnson & Johnson (JNJ) in a $500M R&D funding deal over 2026–2027 to support the development of a new autoimmune treatment.
- JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases.
- Source: Press Release
More on Royalty Pharma, Johnson & Johnson
- Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios
- Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Nanobiotix gains after report on J&J buyout bid
- U.S. starts seeking drugmakers’ views in turning Trump's pricing deals into law
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
